Stockreport

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Corporation  (GKOS) 
Last glaukos corporation earnings: 2/27 04:15 pm Check Earnings Report
PDF Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare [Read more]